vs

Side-by-side financial comparison of Columbia Financial, Inc. (CLBK) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $68.8M, roughly 1.1× Columbia Financial, Inc.). On growth, Columbia Financial, Inc. posted the faster year-over-year revenue change (29.7% vs -36.9%). Columbia Financial, Inc. produced more free cash flow last quarter ($58.6M vs $-6.6M). Over the past eight quarters, Columbia Financial, Inc.'s revenue compounded faster (17.7% CAGR vs -34.4%).

Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota. It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

CLBK vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.1× larger
MED
$75.1M
$68.8M
CLBK
Growing faster (revenue YoY)
CLBK
CLBK
+66.6% gap
CLBK
29.7%
-36.9%
MED
More free cash flow
CLBK
CLBK
$65.2M more FCF
CLBK
$58.6M
$-6.6M
MED
Faster 2-yr revenue CAGR
CLBK
CLBK
Annualised
CLBK
17.7%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLBK
CLBK
MED
MED
Revenue
$68.8M
$75.1M
Net Profit
$15.7M
Gross Margin
69.4%
Operating Margin
28.6%
-10.4%
Net Margin
22.8%
Revenue YoY
29.7%
-36.9%
Net Profit YoY
173.9%
EPS (diluted)
$0.15
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBK
CLBK
MED
MED
Q4 25
$68.8M
$75.1M
Q3 25
$67.3M
$89.4M
Q2 25
$63.9M
$105.6M
Q1 25
$58.8M
$115.7M
Q4 24
$46.4M
$119.0M
Q3 24
$54.3M
$140.2M
Q2 24
$53.3M
$168.6M
Q1 24
$49.7M
$174.7M
Net Profit
CLBK
CLBK
MED
MED
Q4 25
$15.7M
Q3 25
$14.9M
$-2.3M
Q2 25
$12.3M
$2.5M
Q1 25
$8.9M
$-772.0K
Q4 24
$-21.2M
Q3 24
$6.2M
$1.1M
Q2 24
$4.5M
$-8.2M
Q1 24
$-1.2M
$8.3M
Gross Margin
CLBK
CLBK
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
CLBK
CLBK
MED
MED
Q4 25
28.6%
-10.4%
Q3 25
29.5%
-4.6%
Q2 25
25.8%
-1.0%
Q1 25
20.4%
-1.1%
Q4 24
-57.6%
0.6%
Q3 24
13.5%
1.5%
Q2 24
9.0%
-4.7%
Q1 24
-2.6%
4.5%
Net Margin
CLBK
CLBK
MED
MED
Q4 25
22.8%
Q3 25
22.1%
-2.5%
Q2 25
19.3%
2.3%
Q1 25
15.1%
-0.7%
Q4 24
-45.7%
Q3 24
11.4%
0.8%
Q2 24
8.5%
-4.8%
Q1 24
-2.3%
4.8%
EPS (diluted)
CLBK
CLBK
MED
MED
Q4 25
$0.15
$-1.64
Q3 25
$0.15
$-0.21
Q2 25
$0.12
$0.22
Q1 25
$0.09
$-0.07
Q4 24
$-0.20
$0.08
Q3 24
$0.06
$0.10
Q2 24
$0.04
$-0.75
Q1 24
$-0.01
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBK
CLBK
MED
MED
Cash + ST InvestmentsLiquidity on hand
$340.8M
$167.3M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$1.2B
$198.9M
Total Assets
$11.0B
$248.0M
Debt / EquityLower = less leverage
1.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBK
CLBK
MED
MED
Q4 25
$340.8M
$167.3M
Q3 25
$253.4M
$173.5M
Q2 25
$248.2M
$162.7M
Q1 25
$256.1M
$164.6M
Q4 24
$289.2M
$162.3M
Q3 24
$283.5M
$170.0M
Q2 24
$391.1M
$163.5M
Q1 24
$373.5M
$156.4M
Total Debt
CLBK
CLBK
MED
MED
Q4 25
$1.2B
Q3 25
$1.3B
Q2 25
$1.3B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$1.4B
Q2 24
$1.7B
Q1 24
$1.5B
Stockholders' Equity
CLBK
CLBK
MED
MED
Q4 25
$1.2B
$198.9M
Q3 25
$1.1B
$214.7M
Q2 25
$1.1B
$216.0M
Q1 25
$1.1B
$211.0M
Q4 24
$1.1B
$210.1M
Q3 24
$1.1B
$207.3M
Q2 24
$1.0B
$205.3M
Q1 24
$1.0B
$211.0M
Total Assets
CLBK
CLBK
MED
MED
Q4 25
$11.0B
$248.0M
Q3 25
$10.9B
$268.2M
Q2 25
$10.7B
$269.3M
Q1 25
$10.6B
$280.0M
Q4 24
$10.5B
$284.2M
Q3 24
$10.7B
$291.2M
Q2 24
$10.8B
$293.5M
Q1 24
$10.6B
$302.8M
Debt / Equity
CLBK
CLBK
MED
MED
Q4 25
1.02×
Q3 25
1.11×
Q2 25
1.14×
Q1 25
1.01×
Q4 24
1.00×
Q3 24
1.32×
Q2 24
1.61×
Q1 24
1.47×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBK
CLBK
MED
MED
Operating Cash FlowLast quarter
$68.4M
$-5.3M
Free Cash FlowOCF − Capex
$58.6M
$-6.6M
FCF MarginFCF / Revenue
85.1%
-8.8%
Capex IntensityCapex / Revenue
14.3%
1.8%
Cash ConversionOCF / Net Profit
4.36×
TTM Free Cash FlowTrailing 4 quarters
$95.1M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBK
CLBK
MED
MED
Q4 25
$68.4M
$-5.3M
Q3 25
$31.0M
$12.1M
Q2 25
$14.6M
$-3.4M
Q1 25
$-1.6M
$3.4M
Q4 24
$33.3M
$-4.9M
Q3 24
$-28.3M
$9.1M
Q2 24
$18.6M
$13.1M
Q1 24
$14.1M
$7.3M
Free Cash Flow
CLBK
CLBK
MED
MED
Q4 25
$58.6M
$-6.6M
Q3 25
$28.1M
$10.8M
Q2 25
$12.9M
$-4.8M
Q1 25
$-4.5M
$1.9M
Q4 24
$25.9M
$-7.2M
Q3 24
$-31.1M
$7.7M
Q2 24
$17.2M
$11.1M
Q1 24
$12.5M
$5.4M
FCF Margin
CLBK
CLBK
MED
MED
Q4 25
85.1%
-8.8%
Q3 25
41.8%
12.0%
Q2 25
20.2%
-4.5%
Q1 25
-7.6%
1.6%
Q4 24
55.7%
-6.1%
Q3 24
-57.3%
5.5%
Q2 24
32.3%
6.6%
Q1 24
25.1%
3.1%
Capex Intensity
CLBK
CLBK
MED
MED
Q4 25
14.3%
1.8%
Q3 25
4.2%
1.5%
Q2 25
2.7%
1.3%
Q1 25
4.9%
1.3%
Q4 24
16.0%
1.9%
Q3 24
5.1%
1.0%
Q2 24
2.6%
1.1%
Q1 24
3.4%
1.1%
Cash Conversion
CLBK
CLBK
MED
MED
Q4 25
4.36×
Q3 25
2.08×
Q2 25
1.19×
-1.36×
Q1 25
-0.18×
Q4 24
Q3 24
-4.57×
8.04×
Q2 24
4.09×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons